|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | One M Street, SW |
Address2 | Suite 510 |
City | WASHINGTON |
State | DC |
Zip Code | 20003 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 69674-12
|
||||||||
|
6. House ID# 357890000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Leslie Ritter |
Date | 7/20/2022 4:23:20 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R.1319- The American Rescue Plan Act of 2021 - support passage
FY 22 House/Senate Defense Appropriations Act -Supporting -$20 million for the MS Research Program
FY 22 House/Senate Labor, Health and Human Services and Education Act-$500 million for the Agency for Healthcare Research and Quality (AHRQ),$10 billion for the Centers for Disease Control and Prevention (CDC) inclusive of $5 million for the National Neurological Conditions Surveillance Program authorized in the 21st Century Cures Act; $14.2 million for the Lifespan Respite Care Program; Robust support for Medicare and Medicaid and protection of Medicaids current financing structure; and at least $46.1 billion for the National Institute of Health (NIH), full funding for the Patient Centered Outcomes Research Institute (PCORI); and at least $13.5 billion for the Social Security Administrations administrative budget.
FY 22 House/Senate - Military Construction, Veterans Affairs, and Related Agencies Appropriations bill - sustainable, predictable funding for the VA Multiple Sclerosis Centers of Excellence. Additionally, we urge this Committee to include report language that expresses its support for all the Neurology Centers of Excellence in the FY22 appropriations report language. Our suggested language is below:
Neurology Centers of Excellence. - The Committee recognizes the increasing number of Veterans affected by neurologic conditions, including but not limited to epilepsy, headache, multiple sclerosis, and Parkinson's disease. The Department is directed to significantly increase its investment to maintain and expand existing centers of excellence within the VA dedicated to these conditions to enhance their value in coordinating innovative clinical care, education, and research efforts. No later than 120 days after enactment of this Act the Committee directs the Secretary to submit a report to the Committees providing details on opportunities to enhance care for veterans with neurologic conditions, including potential collaboration between the neurology centers of excellence.
H. Res. 101/S.Con.Res.5 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, support passage
FY2023 Defense Appropriations Act- support $22 million for the MS Research Program
FY2023 LHHS Appropriations Act - at least $49 billion for the NIHs base and that any funding for the new ARPA-H, or for other targeted programs like pandemic preparedness, supplement the $49 billion recommendation for NIHs base budget, at least $5 million for the CDC National Neurological Conditions Surveillance System
FY23-House/Senate Military Construction, VA and Related Agencies Appropriations bill - supporting double funding for the VA MS Centers of Excellence ($5 million) and the following report language - Neurology Centers of Excellence. - The Committee recognizes the increasing number of
Veterans affected by neurologic conditions, including but not limited to: epilepsy, headache,
multiple sclerosis, and Parkinson's disease. The Neurology Centers of Excellence provide
essential innovative clinical care, education, and research efforts focused on these
conditions. The Committee applauds the Department for its recent investments into the
headache and epilepsy centers and encourages their continued ongoing support and
. The Committee directs the Department to make similar investments in the
multiple sclerosis and Parkinsons disease centers, which have not received a significant
increase in funding for nearly 20 years. This bill includes at least the following amounts for
maintaining and expanding the Neurology Centers of Excellence: $19,000,000 for epilepsy.
$25,000,000 for headache; $5,000,000 for multiple sclerosis; and $16,000,000 forParkinsons disease.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Ritter |
|
|
|
Bari |
Talente |
|
|
|
Nicole |
Boschi |
|
|
|
Natasha |
Silva |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 1319 - American Rescue Plan Act of 2021 - support passage
H.R. 5376, Build Back Better Act, support passage
S. 898- Fair Accountability and Innovative Research Drug Pricing Act of 2021 - support passage
S. 368/H.R. 1332 - Telehealth Modernization Act - support passage
S.464/H.R. 2163- Safe Step Act, support passage
H.R. 366 - Protecting Access to Post-COVID-19 Telehealth Act of 2021 - support passage
H.R. 4418 - SPIKE Act- "To amend title XI of the Social Security Act to provide for drug manufacturer price transparency."- support passage
S.2210-."Better Care Better Jobs Act"- support passage
S.2164- "Lower Costs, More Cures Act of 2021"- support passage
S.1524/H.R. 3029- "Health Care PRICE Transparency Act"- support passage
S.1428/H.R. 2891-"Preserve Access to Affordable Generics and Biosimilars Act"- support passage
S.1427/H.R. 2869-"Increasing Access to Biosimilars Act of 2021"- support passage
H.R.2846-"Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021"-support passage
H.R.2843-"STOP GAMES Act of 2021"- support passage
H.R.3-"Elijah E. Cummings Lower Drug Costs Now Act" - support passage
H.R.2855-"Star Rating for Biosimilars Act"- support passage
S.164-"Advancing Education on Biosimilars Act of 2021"- support passage
H.R.19- "Lower Costs, More Cures Act of 2021"- support passage
Wyden Releases Principles For Lowering Drug Prices for Americans, support passage
H.R. 2503, Social Determinants Accelerator Act of 2021, support passage
S.1524/H.R.3029- Health Care Price Transparency Act, support passage
H.R. 2884- Affordable Prescriptions for Patients Through Improvement t o Patent Litigation Act, support passage
H.R. 2873- Affordable Prescriptions for Patients Through Promoting Competition Act of 2021, support passage
H.R. 5365, Primary Health Services Enhancement Act, support passage
H.R. 2575, Social Security Disability Insurance Return to Work Act, monitor for position determination
S.2565- Expanding Access to Palliative Care Act, monitor for impact on people affected by MS
H.R. 4714- Disabled Access Credit Expansion Act of 2021- support passage
S. 1435, Affordable Prescriptions for Patients Act of 2021, monitor for position determination
H.R. 3971, Double Dip Elimination Act, monitor for position determination
H.R. 3765, Disability Employment Incentive Act, support passage
H.R. 5801, Help Copays Act, support passage
Healthy Futures Task Force- monitoring subcommittee recommendations and plans for health priorities in the 118th Congress
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Ritter |
|
|
|
Nicole |
Boschi |
|
|
|
Bari |
Talente |
|
|
|
Natasha |
Silva |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.3 - Elijah Cummings Lower Drug Costs Now, monitor legislation
S.151- "COVID HCBS Relief Act of 2021"- support passage
H.R. 4131- "To amend title XIX of the Social Security Act to expand access to home and community-based services (HCBS) under Medicaid, and for other purposes."- support passage
H.R. 2455 - The Resetting the IMPACT Act (TRIA) of 2021." - support passage
H.R. 1319- The American Rescue Plan Act of 2021, support passage
H.R. 2815, BIOSIM Act, support passage
H.R. 2855, the STAR Rating for Biosimilars Act, support passage
H.R. 2846- Ensuring Access to Lower-Cost Medicines for Seniors Act of 021 - support passage
S.2210/H.R. 4131- Better Care Better Jobs Act - support passage
S.2315- Medicaid Saves Lives Act, support passage
S.2327- Seniors Prescription Drug Relief Act- support passage
S.2562-Choose Home Care Act of 2021- support passage
S.2612- Prevent Interruptions in Physical Therapy Act of 2021- support passage
S. 2694- Nursing Home Improvement and Accountability Act of 2021 - support passage
H.R. 5011- Choose Medicare Act, support passage
H.R. 5099- Lowering Medicare Premiums and Prescription Drug Costs Act, support passage
H.R. 5165 - Improving Medicare Coverage Act - support passage
H.R. 5237 - "To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes." - monitor for position determination
H.R. 5260 - Reduced Costs and Continued Cures Act - monitor for position determination
H.R. 5536 - SMART Act - support passage
H.R. 5514 Choose Home Care Act of 2021, support passage
Senate Reconciliation/Senate Finance prescription drug pricing package - supporting provisions that allow Medicare to negotiate for a specific amount of drugs, implement a $2,000 out-of-pocket cap on drug costs in Medicare Part D and a smoothing mechanism so that people in Medicare can spread their costs over the course of the year, and limit drug price increases by implementing rebates if prescription drug prices rise faster than inflation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bari |
Talente |
|
|
|
Nicole |
Boschi |
|
|
|
Leslie |
Ritter |
|
|
|
Natasha |
Silva |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R. 7667- Food and Drug Amendments of 2022, support passage
S.4248- Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, support passage
H.R. 5435- BRAIN Act of 2021, establishing a Neuroscience Center of Excellence at the Food and Drug Administration, support passage
H.R.315 - Common Sense Cannabis Reform for Veterans, Small Business and Medical Professionals Act, monitor to support
H.R. 6000 - Cures 2.0 Act, supporting the goals of Rep. Upton/DeGette's Cures 2.0 initiative aimed at accelerating medical research, patient access to novel therapeutics and authorizing the Administration's Advanced Research Projects Agency for Health (ARPA-H) proposal -support passage
S. 3726- CARE for Long COVID Act- support passage
S.4447 - Modernizing Accelerated Approval Act, support passage and inclusion in Senate FDASLA package.
S. 3799 Prevent Pandemics Act - support passage
Lisa Blunt Rochester- Long-COVID RECOVERY NOW Act, support passage (bill number forthcoming)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Ritter |
|
|
|
Nicole |
Boschi |
|
|
|
Natasha |
Silva |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
H.R. 3684 - Infrastructure Investment and Jobs Act/Investing in a New Vision for the Environment and Surface Transportation in America Act or the INVEST in America Act, support passage
S.1680/H.R. 3317 - All Stations Accessibility Act of 2021 (ASAP Act), support passage and inclusion in Bipartisan Infrastructure Act/H.R. 3684
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Ritter |
|
|
|
Nicole |
Boschi |
|
|
|
Bari |
Talente |
|
|
|
Natasha |
Silva |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CIV
16. Specific lobbying issues
H.R. 1319 - American Rescue Plan Act - support passage
COVID-19 vaccine prioritization and distribution - supported policies ensuring people with conditions that placed them at a higher risk of severe covid-19 were able to be prioritized in CDC-ACIP recommendation and for vaccine distribution plans.
Supporting updates and changes Supplemental Security Income (SSI) program to increase the benefit to at least the federal poverty level, increase and index resource limits, eliminate marriage penalties, eliminate outdated rules about in-kind support from friends and family, and update outdated income disregards.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Ritter |
|
|
|
Nicole |
Boschi |
|
|
|
Bari |
Talente |
|
|
|
Bari |
Talente |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
S.243- Legacy IRA Act - support passage
H.R.1219/S.331- ABLE Age Adjustment Act- increases age threshold for tax-favored ABLE accounts- support passage
S.1670/H.R.3321- Credit for Caring Act, support passage
S.2481 - Disabled Access Credit Expansion Act of 2021, support passage
H.R. 2954- Securing a Strong Retirement Act of 2021 (SECURE Act), support passage
Enhancing American Retirement Now Act (bill number forthcoming, Senate Finance retirement package), support passage
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bari |
Talente |
|
|
|
Leslie |
Ritter |
|
|
|
Natasha |
Silva |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code WEL
16. Specific lobbying issues
H.R. 804, the FAMILY Act to entitle employees to a family and medical leave insurance monthly benefit for 2 months of qualified caregiving- support passage.
Supporting proposals to include Paid Family and Medical Leave policies and provisions within the H.R. 5376, the Build Back Better Act, support passage
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Ritter |
|
|
|
Bari |
Talente |
|
|
|
Nicole |
Boschi |
|
|
|
Natasha |
Silva |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | One M Street, SW, Suite 510 |
||||||
City | Washington |
State | DC |
Zip Code | 20003 |
Country | USA |
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |